$28.04−0.55 (−1.92%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Celldex Therapeutics (CLDX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
16 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 78% below its peak, net margin −16748.0%. Worth your attention in FY25: Share count (+54.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼78.0%
1.5
FY21→FY25CAGR −24.1%/yr
Net income ($M)▼63.9%
−258.8
FY21→FY25CAGR —
Free cash flow ($M)▼33.8%
−213.7
FY21→FY25CAGR —
Diluted EPS▼59.2%
−3.90
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+54.9%
42.9mn → 66.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$2.7M
+41.4% YoY in FY25 · 175.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-16748¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -16748.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 157.0 | 1,545.0 | 7,020.0 | 6,883.0 | 2,357.0 | 4,651.0 | ▼78.0% | −24.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 4,651.0 | — | — |
Research & development | 283,283.0 | 245,074.0 | 163,550.0 | 118,011.0 | 82,258.0 | 53,311.0 | ▲49.8% | +46.4% |
Selling, general & admin | 51,337.0 | 43,838.0 | 38,548.0 | 30,914.0 | 27,195.0 | 20,488.0 | ▲13.7% | +20.9% |
Total operating expenses | 334,620.0 | 288,912.0 | 202,098.0 | 161,425.0 | 117,591.0 | 75,894.0 | ▲43.0% | +39.7% |
Operating incomefeeds ROC rank | −334,463.0 | −287,367.0 | −195,078.0 | −154,542.0 | −115,234.0 | −71,243.0 | ▼47.3% | — |
Other income, net | 25,401.0 | 28,610.0 | 37,215.0 | 13,113.0 | 2,909.0 | 505.0 | — | — |
Pretax income | −309,062.0 | −258,757.0 | −157,863.0 | −141,429.0 | −112,325.0 | −70,738.0 | ▼63.9% | — |
Income tax | — | — | — | — | — | −227.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −309,062.0 | −258,757.0 | −157,863.0 | −141,429.0 | −112,325.0 | −70,511.0 | ▼63.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −4.31 | −3.90 | −2.45 | −2.92 | −2.40 | −1.64 | ▼59.2% | — |
Diluted shares (mn) | 78.53 | 66.42 | 64.39 | 48.45 | 46.89 | 42.87 | ▲3.1% | +11.6% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −213033.8% | −18599.8% | −2778.9% | −2245.3% | −4889.0% | −1531.8% | ▼15820.9pp | −17068.0pp |
Net margin | −196854.8% | −16748.0% | −2248.8% | −2054.8% | −4765.6% | −1516.0% | ▼14499.3pp | −15232.0pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Celldex Therapeutics' revenue last fiscal year?
Celldex Therapeutics reported revenue of $1.5M in fiscal 2025, down 78.0% from fiscal 2024.
What was Celldex Therapeutics' net income?
Celldex Therapeutics reported net income of −$258.8M in fiscal 2025, a net margin of −16748.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

